Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2024
2024
Date
Title
2024-12-17
Oneness announces the information about the investor’s conference of 2024 Q4.
>
2024-11-12
(Supplementary Explanation) Announcement of the Company’s board of directors’ resolution on the change of the cash capital increase plan for 2020
>
2024-11-11
Announcement of the Company’s board of directors’ resolution on the change of the cash capital increase plan for 2020
>
2024-11-11
The Company’s 2024Q3 consolidated financial statements have been approved by the Board of Directors
>
2024-11-04
Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds for Saudi Arabia
>
2024-10-30
Announcement of the date of the Company’s board of directors meeting for the Thired Quarter of 2024 Consolidated Financial Reports
>
2024-09-27
A US patent titled “Biomarkers for lung cancer stem cells” has been granted
>
2024-09-27
Oneness Biotech Co., Ltd. receives a United States patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.
>
2024-09-20
Oneness has received medical device registration approval on Bonvadis Topical Cream for Egypt
>
2024-09-18
Oneness announces the information about the investor’s conference of 2024 Q3.
>
2024-09-15
National Health Security Administration of China has not included Fespixon Cream in this year NRDL adjustment negotiation after the expert review.
>
2024-09-08
SNS812 Phase 2 study demonstrated statistical significance in treating COVID-19 based on its safety, precision and broad-spectrum efficacy.
>
2024-09-08
Oneness & Microbio (Shanghai) host an international press conference to present the pan-COVID new drug, SNS812 Phase 2 clinical trial results and future prospects
>
2024-09-05
The post hoc analysis of the global novel drug, Fespixon (ON101), on hard-to-heal diabetic foot ulcers has been published in Advances in Wound Care
>
2024-09-05
The Company’s security trading have reached threshold of mandatory disclosure of financial information per TPEx requirements
>
1
2
3
…
5
Next »
